Skip to main content
. 2019 Apr 25;9:323. doi: 10.3389/fonc.2019.00323

Figure 5.

Figure 5

In vitro cellular analysis show that resistant MDA-MB-231 cells, treated with four cycles of Adriamycin and cyclophosphamide and four cycles of Paclitaxel (mimicking the clinical treatment setting of breast cancer), caused an increase in the levels of soluble (A) and cellular NRP-1 (B) detected by ELISA and western blot, respectively.